Hollie Franklin, Author at Drugs in Context

Presentation and pathophysiology of neuro-COVID

Josef Finsterer, Fulvio Alexandre Scorza, Carla Alexandra Scorza

Article Type

Letter-to-the-Editor

Published

12 Aug 2021

Letter to the Editor commenting on Orsucci D, Caldarazzo Ienco E, Nocita G, Napolitano A, Vista M. Neurological features of COVID-19 and their treatment: a review. Drugs Context. 2020;9:2020-5-1.

Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions

Amalia Leceta, Aintzane García, Ander Sologuren, Cristina Campo

Article Type

Review

Published

10 Aug 2021

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma

Francesco Serra, Carlotta Faverio, Angioletta Lasagna, Stefania Barruscotti, Tommaso Dominioni, Marco Benazzo, Paolo Pedrazzoli, Silvia Chiellino

Article Type

Review

Published

09 Aug 2021

The aim of this review is to investigate the role of treatment beyond progression and locoregional approaches in BRAF-mutated metastatic melanoma and provide oncologists dealing with this malignancy a useful road map on when and why to choose this strategy.

Oscillococcinum® for upper respiratory tract infections and exacerbations in COPD: an observational, prospective study (OXITUNIS)

Hichem Aouina, Anis Bamri, Aurélien Vesin, Karine Danno, Eléonore Aubry, Cécile Faure, Naoual Boujedaini

Article Type

Original Research

Published

29 Jul 2021

This article discussese the effectiveness of Oscillococcinum® in the protection from upper respiratory tract infections in patients with chronic obstructive pulmonary disease who had been vaccinated against influenza infection over the 2018–2019 winter season.

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide

Sarah M Michienzi, Mikayla Johnson, Thomas D Chiampas, Eric Wenzler, Rodrigo M Burgos, Renata O Smith, Melissa E Badowski

Article Type

Original Research

Published

23 Jul 2021

The goal of this retrospective analysis is to assess changes in virological suppression, immunological status, renal function, weight and body mass index (BMI) amongst people living with HIV who switched from a tenofovir disoproxil fumarate-based to a tenofovir alafenamide-based regimen.